

SUGGESTED PROCEDURE

Item	Omeprazole 2mg/ml Suspension (60ml)	Formula Date	22 Sep 2022
API(s)	Omeprazole, USP	Procedure No.	P2571
Base	SuspendRx SF Alka, Unflavored	Revision	R3
		Compound Type	Alkaline Suspension

Beyond Use Date Estimate (at time of revision): TBD (in test) ¹

Rx	Unit of Measure	Comment
Omeprazole, USP	120mg	
SuspendRx SF Alka Unflavored	3.1g	
Purified Water	60ml Q.S.	

Method of Preparation

1. Weigh Omeprazole and add to pre-weighed SuspendRx SF Alka Unflavored (3.1g in a 20 dram (73.9ml) amber graduated bottle).
2. Recap bottle and shake vigorously.
3. Add 50ml of purified water to the omeprazole/Suspend SF Alka powder mixture and secure cap. The use of a graduated cylinder for measuring the appropriate purified water aliquots is recommended.
4. Shake vigorously by hand for no less than 60 seconds until uniform.
5. Add additional purified water to achieve the final volume in an appropriate container (60ml) and then shake to form a uniform suspension.
6. Suggested Quality Assessments – follow pharmacy SOPs:
 - a. Weight to volume calculation
 - b. Color
 - c. Pourability
 - d. Settling
 - e. Resuspendability

Store in air-tight, light-resistant plastic containers

Store at Refrigerated Temperature

¹ Even though the buffered pH range is considered inhibitory to microbial growth, microbial results may vary depending on multiple factors that may include water quality, environment, and aseptic technique for SuspendRx™ Alka and other reconstituted alkaline type suspension vehicles that are preservative-free.

Beyond-Use Date should be based on the current USP General Chapter <795>. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist. Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

WARNING! Precautions should be taken when handling APIs as they can be absorbed through the skin, mucus membranes and lungs if inhaled. Always wear protective lab apparel, gloves, eye protection, respirator / work under a safety cabinet.

Disclaimer: SpecializedRx makes no warranties or claims to the safety, accuracy, or efficacy of the above information, expressed or implied given the variations in use, materials, and formulations. SpecializedRx accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold SpecializedRx and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein. This is a copywritten© formula that may not otherwise be distributed, copied or disclosed without SRx's written permission. This formula is subject to SRx intellectual property rights.